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Background/aim: This study aimed to investigate the change in bone mineral density (BMD) before and 1 year after parathyroidectomy
in patients with primary hyperparathyroidism (PHPT).
Materials and methods: The clinical and biochemical parameters and DEXA screening of patients with symptomatic PHPT (n = 28)
and asymptomatic PHPT (n = 63) were investigated before and 1 year after parathyroidectomy.
Results: Patients with symptomatic PHPT had a higher prevalence of nephrolithiasis (18.2% vs. 4.6%, P = 0.032) when compared to the
prevalence in patients with asymptomatic PHPT. The prevalence of osteoporosis in the lumbar spine (63.0% vs. 37.5%, P = 0.026) and
femoral neck (40.7% vs. 20.6%, P = 0.048) was higher in symptomatic PHPT when compared to the prevalence in asymptomatic PHPT.
After parathyroidectomy, the decreases in the prevalence of osteoporosis in the lumbar spine (25.8% vs. 9.4%, P = 0.014), femoral neck
(22.1% vs. 8.2%, P =0.009), and total hip (22.4% vs. 5.3%, P = 0.007) were higher in symptomatic PHPT compared to the asymptomatic
PHPT group. A higher BMD gain (g/cm2) was seen in the lumbar spine (10.83% vs. 4.65%, P=0.016) and femoral neck (12.61% vs.
4.37%, P=0.005) in symptomatic PHPT compared to the asymptomatic PHPT group.
Conclusion: Parathyroidectomy provided more BMD gain in the lumbar spine and femoral neck in patients with symptomatic PHPT
when compared to patients with asymptomatic PHPT 1 year after parathyroidectomy.
Key words: Bone mineral density, parathyroidectomy, hyperparathyroidism

1. Introduction
Patients with elevated serum parathyroid hormone
(PTH) and calcium levels are defined as having primary
hyperparathyroidism (PHPT). Asymptomatic primary
PHPT is characterized as a disorder without signs or
symptoms associated with PTH and calcium excess [1].
Many patients with asymptomatic PHPT report nonspecific
symptoms such as weakness, depression, anxiety, fatigue,
loss of initiative, disturbed sleep, decreased memory and
cognitive function, constipation, polydipsia, and pain in
the extremities [1,2]. Nowadays, classic features of PHPT
such as stones, abdominal groans, psychic moans, and
fragile fractures of bones are not commonly observed
because of routine biochemical analyses [2]. Most cases
of PHPT are discovered incidentally upon biochemical
testing when patients are mild and asymptomatic [3].
The disease presents more subtly; therefore, surgery
management remains a clinical dilemma. The National
Institutes for Health (NIH) consensus guidelines for the

management of asymptomatic PHPT recommend surgery
in the event of serum calcium of ≥1 g/dL above the upper
limit of normal or a previous fragility fracture or an energy
X-ray absorptiometry (DEXA) score of less than –2.5 at
any site or estimated glomerular filtration rate of <60 mL/
min or the patient is aged <50 years or medical follow-up
is undesired or impractical [2].
PHPT is associated with osteoporosis/osteopenia;
however, overt complications of the skeleton are rarely
encountered nowadays [1]. Overt complications of the
disease such as osteitis fibrosa cystica, salt-and-pepper
sign, periosteal bone resorption, bone cysts, and brown
tumors are commonly seen in classic PHPT [2]. These
findings generally are not observed in asymptomatic
PHPT but DEXA and bone biopsies reveal skeletal
involvement. Both trabecular and cortical bones are
affected in asymptomatic patients with PHPT [3].
Epidemiologic studies have revealed an increased risk of
both vertebral and nonvertebral fractures in patients with
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PHPT [4,5]. Increased bone turnover [6], decreased bone
mineral density (BMD) score [7], and increased risk of
fragile fracture [8] have been observed in asymptomatic
patients PHPT, even in the early phase of the disease.
BMD measurement in the lumbar spine, a trabecular site,
is relatively preserved, whereas the distal one-third of
the radius, a cortical site, is reduced. PHPT has a greater
catabolic effect on the cortical bone but a relatively sparing
effect on trabecular bone. Bone remodeling slows down,
and the BMD score subsequently increases and fragile
bone fractures decrease after a biochemical cure provided
by a successful parathyroidectomy [6,9–13]. The BMD
scores are improved after successful parathyroidectomy
in patients with mild PHPT [12,14]. Successful
parathyroidectomy in symptomatic PHPT increases
BMD the most, and the fastest is in the lumbar spine and
hip, followed later by increases in the distal 1/3 of the
radius. PHPT patients with severe skeletal involvement
benefit more from successful parathyroidectomy [15–18].
However, the effect of surgical treatment on the skeleton
in asymptomatic PHPT remains unclear. This study aimed
to investigate the change in BMD before and 1 year after
parathyroidectomy in patients with PHPT.
2. Materials and methods
Patients with PHPT who were referred to our tertiary
hospital (Ankara, Turkey), in the Department of
Endocrinology and Metabolism, from 2011 to 2014, were
recruited for this prospective study. Most of the patients
presented with osteoporosis and symptoms unrelated to
hyperparathyroidism. Each patient gave informed consent
as per the Declaration of Helsinki. This study was approved
by the Dışkapı Yıldırım Beyazıt Teaching and Research
Hospital Ethics Board (Number: 24.02.2013-12/21).
We tested for symptoms related to hypercalcemia
(repeated nephrolithiasis, gastritis, polyuria, muscle
weakness, osteoporosis, or psychiatric disorders) and bone
fractures. Patients with a hypercalcemic crisis, defined
as serum calcium of ≥14 mg/dL, were not included.
Patients with Cushing’s syndrome, osteomalacia, renal
insufficiency, hepatic disorders, rheumatoid arthritis,
and ankylosing spondylitis were excluded. No patients
used bisphosphonates, calcimimetic agents, hormone
replacement treatment, selective estrogen receptor
modulators, or cortisol before the start of the study or
after parathyroidectomy. However, five patients had
hungry bone syndrome following parathyroidectomy, and
five patients started taking active vitamin D3 (calcitriol)
soon after parathyroidectomy. Three patients began
treatment with calcium acetate, and two patients used
both. Patients who had serum vitamin D of <20 ng/mL
were given vitamin D3 at 50,000 IU/week for 8 weeks and
subsequent daily oral dosages of 800 IU vitamin D3 after

parathyroidectomy. Patients who had fragile fractures
were not included.
We excluded patients without follow-up (n = 19) from
the study. In the end, we only included 91 patients with
complete data in the study. We stratified patients into
two groups as having symptomatic PHPT (n = 28) or
asymptomatic PHPT (n = 63). Asymptomatic primary
hyperparathyroidism described patients who lacked
obvious signs and symptoms associated with either elevated
calcium or parathyroid hormone. We included patients
with asymptomatic PHPT requiring parathyroidectomy
in this study. We set the criteria for parathyroidectomy as
in the NIH recommendations [2]. A single surgical group
performed all operations. All patients had the following
characteristics: a) biochemical and clinical diagnosis of
PHPT, b) successful parathyroidectomy as confirmed by
normal postparathyroidectomy serum calcium levels,
and c) follow-up with clinical, biochemical, and BMD
assessment before and after parathyroidectomy.
Clinical,
biochemical,
and
anthropometric
measurements were performed before and after
parathyroidectomy. Body mass index (BMI) was calculated
as weight (kg) / height (m2). Serum calcium, phosphorus,
25-hydroxy vitamin D3 (25OHD), intact parathyroid
hormone (iPTH), alkaline phosphatase (ALP), thyroidstimulating hormone (TSH), creatinine, albumin,
glucose, and urinary calcium excretion were measured.
We measured serum iPTH using a radioimmunoassay
(DiaSorin Inc., Stillwater, MN, USA). We checked
successful parathyroidectomies in all patients at 3, 6, and 12
months through normalization of serum calcium. We used
DEXA and renal ultrasound to determine the advisability of
surgery in asymptomatic patients and to monitor patients.
Clinically silent nephrolithiasis and nephrocalcinosis
were detected using renal ultrasonography before
parathyroidectomy while investigating the criteria for
surgery. BMD measurements in the lumbar spine (L1–
L4), hips, and femoral neck were performed before and
after parathyroidectomy using DEXA (Hologic QDR4500 device, Hologic Inc., Waltham, MA, USA). BMD
is expressed in grams per square centimeter (g/cm2) and
as standard deviations (T-scores). BMD change (%) was
assessed using the following formula: (postoperative
– preoperative BMD / preoperative BMD) × 100 [17].
Osteoporosis was diagnosed as a BMD T-score of less than
or equal to –2.5 SD in the lumbar spine, hip, or femoral
neck [2].
2.1. Statistical analysis
Statistical analysis was performed using SPSS 18.0 (SPSS
Inc., Chicago, IL, USA). Variables are presented as mean ±
standard deviation (SD) or median (min–max), percentage
(%), odds ratio (OR), and 95% confidence interval (CI).
Normality was tested using Kolmogorov–Smirnov and
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Shapiro–Wilk W tests. The chi-square test or Fisher’s
exact test was used for categorical variables. Student’s
t-test was used for normally distributed continuous
variables. The Mann–Whitney U test was used for
continuous variables that were not normally distributed.
McNemar’s test was used for categorical variables between
preparathyroidectomy
and
postparathyroidectomy
values. The paired-samples t-test was used for
normally distributed continuous variables between
preparathyroidectomy and postparathyroidectomy. The
Wilcoxon test was used for continuous variables that were
not normally distributed between preparathyroidectomy
and postparathyroidectomy. Logistic regression analysis
was performed: BMD gain was defined as the dependent
variable and preparathyroidectomy variables such as
adenoma volume, iPTH, ALP, and symptoms were
independent variables. Variables identified with a P-value
of ≤0.1 were entered in the model. Statistical significance
was defined as P < 0.05.
3. Results
Among the patients with PHPT, 69.2% were asymptomatic.
Sex, menopause, age, BMI, and smoking habits were similar
between groups (P > 0.05). Patients with symptomatic PHPT
had a higher prevalence of nephrolithiasis (18.2% vs. 4.6%,
P = 0.032) and higher adenoma volume (2.95 ± 3.49 vs.
0.47 ± 0.56 cm3, P = 0.027) than seen in the asymptomatic
PHPT group. Serum calcium, ALP, and iPTH were higher
in patients with symptomatic PHPT than in patients with
asymptomatic PHPT (P < 0.05). Levels of 25(OH)D and
phosphorus were lower in patients with symptomatic PHPT
than in patients with asymptomatic PHPT (P < 0.05). The
number of patients with at least one site of osteoporosis
was higher in symptomatic PHPT patients than in patients
with asymptomatic PHPT (66.7% vs. 39.1%, P = 0.016). The
number of patients with osteoporosis in the lumbar spine
(63.0% vs. 37.5%, P = 0.026) and femoral neck (40.7% vs.
20.6%, P = 0.048) was higher for symptomatic PHPT than
asymptomatic PHPT. Osteoporosis in the total hip did not
differ between the groups (P > 0.05). Total hip and BMD-T
score in the lumbar spine was higher in patients with
symptomatic PHPT than in patients with asymptomatic
PHPT (–2.92 ± 1.17 vs. –1.99 ± 1.41, P = 0.020). The total
hip and femoral neck BMD T-sore did not differ between
the groups (P > 0.05). We detail the clinical parameters of
patients with asymptomatic PHPT or symptomatic PHPT
before parathyroidectomy in Table 1.
3.1. Bone mineral density gain at one year of parathyroidectomy
After successful parathyroidectomy, serum calcium, iPTH,
and ALP were more decreased in patients with symptomatic
PHPT than in patients with asymptomatic PHPT (P <
0.05). Magnesium, 25(OH)D, phosphorus, and BMI did
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not change between the groups (P > 0.05). The decrease in
the number of patients with at least one site of osteoporosis
was higher in patients with asymptomatic PHPT than in
patients with symptomatic PHPT (22.1% vs. 6.3%, P =
0.008). The decrease in the prevalence of osteoporosis
in the lumbar spine (25.8% vs. 9.4%, P = 0.014), femoral
neck (22.1% vs. 8.2%, P = 0.009), and total hip (22.4% vs.
5.3%, P = 0.007) was higher in patients with symptomatic
PHPT than in patients with asymptomatic PHPT. A higher
BMD gain (g/cm2) was seen in the lumbar spine (10.83%
vs. 4.65%, P = 0.016) and femoral neck (12.61% vs. 4.37%,
P = 0.005) in patients with symptomatic PHPT when
compared to patients with asymptomatic PHPT. Total hip
BMD change (g/cm2) did not differ between the groups
(6.57% vs. 3.75%, P > 0.05). The increase in BMD T-score
was higher in the lumbar spine (0.65 ± 0.60 vs. 0.30 ± 0.77,
P = 0.039), femoral neck (0.98 ± 0.94 vs. 0.36 ± 0.67, P =
0.001), and total hip (0.54 ± 0.55 vs. 0.26 ± 0.51, P = 0.021)
in patients with symptomatic PHPT than in patients with
asymptomatic PHPT. Change in clinical parameters after
parathyroidectomy is shown in Table 2.
Univariate analysis showed that BMD gain in the
lumbar spine and femoral neck was positively correlated
with preparathyroidectomy iPTH, pre-ALP, adenoma
volume, and being in the symptomatic PHPT group (Table
3). In the logistic regression analysis, preparathyroidectomy
iPTH was the only variable identified as an independent
predictor of BMD gain (β = 3.18, 95% CI: 2.3–13.5, P =
0.02).
4. Discussion
Our study showed that osteoporosis was more prevalent
in patients with symptomatic PHPT than in patients with
asymptomatic PHPT. Parathyroidectomy reduced the
prevalence of osteoporosis in the lumbar spine, femoral
neck, and total hip with biochemical cure in both patients
with symptomatic PHPT and asymptomatic PHPT 1 year
after parathyroidectomy. Parathyroidectomy provided a
better BMD gain in the lumbar spine and femoral neck
in patients with symptomatic PHPT compared to patients
with asymptomatic PHPT. Preparathyroidectomy iPTH
was an independent predictor of BMD gain.
Trabecular and cortical bone mineral density were
decreased in patients with asymptomatic PHPT and
symptomatic PHPT [3,19–22]. Our study showed a
higher prevalence of osteoporosis in the lumbar spine
and femoral neck in patients with symptomatic PHPT
than in patients with asymptomatic PHPT; however, total
hip osteoporosis was similar between the groups. After a
successful parathyroidectomy, BMD scores were increased
in symptomatic PHPT cases [6,9–11]. Parathyroidectomy
has improved BMD scores in patients with mild PHPT
[12,14]. Successful parathyroidectomy increased BMD scores
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Table 1. Clinical, biochemical, and bone mineral densitometry parameters of patients with asymptomatic and
symptomatic primary hyperparathyroidism before parathyroidectomy.
Variables

Asymptomatic PHPT,
n = 63

Symptomatic PHPT,
n = 28

P

Women (%)

82.8

77.8

0.314

Menopause (%)

61.5

61.9

0.815

Smoking habit (%)

20.6

25.9

0.715

Age (years)

51.52 ± 10.47

52.40 ± 11.59

0.826

BMI (kg/m2)

29.95 ± 4.72

32.13 ± 6.60

0.482

Glucose (mg/dL)

90.85 ± 9.99

89.60 ± 9.01

0.934

Albumin (mg/dL)

4.53 ± 0.22

4.41 ± 0.15

0.352

Creatinine (mg/dL)

0.75 ± 0.15

0.68 ± 0.16

0.408

Calcium (mg/dL)

10.41 ± 0.64

11.34 ± 0.76

<0.001

Phosphorus (mg/dL)

2.61 ± 0.37

2.50 ± 0.44

0.030

iPTH (pg/dL)

194.76 ± 136.63

347.53 ± 202.24

<0.001

ALP (mg/dL)

101.52 ± 40.08

158.20 ± 74.90

<0.001

25(OH)D (ng/mL)

20.15 ± 24.11

9.82 ± 9.13

0.003

Magnesium (mg/dL)

2.13 ± 0.19

2.12 ± 0.23

0.935

TSH (mg/dL)

2.09 ± 1.29

1.56 ± 0.81

0.728

Lumbar spine BMD (g/cm2)

0.83 ± 0.15

0.72 ± 0.12

0.137

Total hip BMD (g/cm )

0.78 ± 0.13

0.71 ± 0.15

0.951

Femoral neck BMD (g/cm2)

0.67 ± 0.11

0.63 ± 0.09

0.879

Lumbar spine T-score

–1.99 ± 1.41

–2.92 ± 1.17

0.020

Total hip T-score

–1.44 ± 1.14

–1.98 ± 1.30

0.242

Femoral neck T-score

–1.83 ± 1.17

–2.32 ± 1.09

0.165

Osteoporosis at lumbar spine (%)

37.5

63.0

0.026

Osteoporosis at total hip (%)

12.5

29.6

0.050

Osteoporosis at femoral neck (%)

20.6

40.7

0.048

Osteoporosis at least one site (%)

39.1

66.7

0.016

Nephrolithiasis (%)

4.6

18.2

0.032

Urinary calcium excretion (mg/24 h)

362.61 ± 175.20

437.33 ± 87.18

0.016

Adenoma volume (cm )

0.47 ± 0.56

2.95 ± 3.49

0.027

2

3

Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as
percentage (%).
BMI, Body mass index; TSH, thyroid-stimulating hormone; ALP, alkaline phosphatase; iPTH, intact parathyroid
hormone, BMD, bone mineral density; 25(OH)D, 25-hydroxy-vitamin D.

the most and fastest in the lumbar spine and hip followed
later by increases in radius, especially in symptomatic PHPT.
Parathyroidectomy has improved severe skeletal involvement
in symptomatic PHPT [15–18]. Our results show that BMD
loss in the femoral neck and lumbar spine was higher in
patients with symptomatic PHPT than in patients with
asymptomatic PHPT. After parathyroidectomy, BMD gain
in the femoral neck and lumbar spine was higher in patients
with symptomatic PHPT than in patients with asymptomatic

PHPT. In our study, we observed that surgery may improve
bone involvement even in asymptomatic PHPT with
osteopenia; therefore, we suggest that parathyroidectomy
may be useful for the treatment of osteopenia/osteoporosis in
asymptomatic PHPT patients.
A study showed that BMD score decreased in the femoral
neck and remained unchanged in the lumbar spine in an
observation group, whereas BMD improved in the lumbar
spine and femoral neck in the parathyroidectomy group [23].
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Table 2. Change in clinical parameters after parathyroidectomy.
Asymptomatic PHPT,
n = 63

Symptomatic PHPT,
n = 28

P

∆ BMI (kg/m2)

0.48 ± 1.31

0.19 ± 0.85

0.282

∆ Calcium (mg/dL)

–1.43 ± 0.68

-3.32 ± 5.82

0.012

∆ Phosphorus (mg/dL)

0.73 ± 0.49

-0.89 ± 0.52

0.168

∆ iPTH (pg/dL)

–128.71 ± 122.86

-297.51 ± 310.81

<0.001

∆ ALP (mg/dL)

–22.82 ± 27.06

-78.25 ± 66.08

<0.001

∆ Magnesium (mg/dL)

–0.13 ± 0.27

0.03 ± 0.24

0.486

Variables

∆ 25(OH)D

14.84 ± 24.12

19.01 ± 9.17

0.379

∆ Lumbar spine BMD (g/cm3) %

4.65 (–10.00 to 30.65)

10.83 (-6.72 - 70.08)

0.016

∆ Total hip BMD (g/cm ) %

3.75 (–11.57 to 21.29)

6.57 (-7.53 - 51.98)

0.124

∆ Femoral neck BMD (g/cm3) %

4.37 (–11.21 to 30.04)

12.61 (-14.17 - 54.85)

0.005

∆ Lumbar spine BMD T-score

0.30 ± 0.77

0.65 ± 0.60

0.039

∆ Total hip BMD T-score

0.26 ± 0.51

0.54 ± 0.55

0.021

∆ Femoral neck BMD T-score

0.36 ± 0.67

0.98 ± 0.94

0.001

∆ Osteoporosis at lumbar spine (%)

25.8

9.4

0.014

3

∆ Osteoporosis at total hip (%)

22.4

5.3

0.007

∆ Osteoporosis at femoral neck (%)

22.1

8.2

0.009

∆ Osteoporosis of at least one site (%)

22.1

6.3

0.008

Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as percentage
(%).
Difference (∆) is shown as change in values before and after treatment (latter value minus former value).
BMI, Body mass index; ALP, alkaline phosphatase; iPTH, intact parathyroid hormone, BMD, bone mineral density;
25(OH)D, 25-hydroxy-vitamin D.
Table 3. Correlation between preparathyroidectomy variables
and BMD gain at lumbar spine and femoral neck

Pre-iPTH
Pre-ALP
Adenoma volume
Symptomatic PHPT group

BMD gain in
lumbar spine

BMD gain in
femoral neck

r*

P

r*

P

0.338
0.319
0.396
0.276

0.124
0.148
0.104
0.015

0.329
0.580
0.201
0.321

0.135
0.005
0.423
0.004

r* represents correlation coefficient.
ALP, Alkaline phosphatase; iPTH, intact parathyroid hormone.

They observed bone loss in the hips in asymptomatic PHPT
cases without surgery [24]. Parathyroidectomy was thought
to be more cost-effective than observation without treatment
in patients with mild asymptomatic PHPT [25]. Postoperative
BMD gain in the femoral neck and total hip with decreasing
bone-specific alkaline phosphatase concentrations have
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been reported in patients with mild asymptomatic PHPT
[12,26,27]. Our results showed that BMD increased by
10.83% in the lumbar spine, by 6.57% in the total hip, and
by 12.61% in the femoral neck in patients with symptomatic
PHPT after parathyroidectomy while BMD increased by
4.65% in the lumbar spine, 3.75% in the total hip, and
4.37% in the femoral neck in patients with asymptomatic
PHPT after parathyroidectomy. However, BMD gain in the
total hip was similar in the two groups. Several studies have
reported significant BMD gain following parathyroidectomy
[14–17,26,28]. The BMD was lower in patients with severe
PHPT and significant improvements were observed after
surgical cure, which is consistent with our results [17,29].
Skeletal abnormalities regressed and osteoclastoma shrunk
with BMD gain following successful parathyroidectomy in
severe PHPT [9,30,31]. Significant and rapid BMD gain was
observed in patients with osteitis fibrosa cystica, whereas
slow BMD gain was observed in patients with asymptomatic
PHPT [11,30,31]. During follow-up over 2 years, stable
BMD gain was observed in PHPT patients who underwent
parathyroidectomy, whereas slow bone loss was observed
in those without parathyroidectomy [32]. BMD gain after
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surgery in asymptomatic PHPT was reported during 1–3 years
of follow-up [12,14,26]. After a successful parathyroidectomy,
significant and rapid BMD gain was observed in the lumbar
spine and hip, followed by BMD gain in the radius [11,27,28].
Long-lasting stable BMD gain was reported at all bone
sites after successful parathyroidectomy in asymptomatic
PHPT [10,11,28]. After successful parathyroidectomy, BMD
gain at 5, 10, and 15 years was observed; however bone
loss in the hip and radius was observed in patients without
parathyroidectomy [11]. Our results showed that BMD was
improved in both patients with symptomatic PHPT and
asymptomatic PHPT after successful parathyroidectomy.
Postoperative BMD gain shows variations among patients
with PHPT. Changes in serum PTH concentration, initial
bone turnover, age, sex, and preoperative vitamin D status are
considered effective for postoperative bone gain [12,18]. Our
study showed that symptomatic PHPT cases had lower serum
25(OH)D level than asymptomatic PHPT. Changes in 25(OH)
D and BMI did not differ between the groups following
parathyroidectomy. Our study showed that BMD gain in
the lumbar spine and femoral neck was positively correlated
with pre-iPTH, pre-ALP, adenoma volume, and having
symptomatic PHPT. Preparathyroidectomy iPTH was the
only independent predictor of BMD gain. These findings may

suggest that BMD gain might be more remarkable in patients
with higher preoperative iPTH. Similarly, a study showed that
postoperative BMD gain was correlated with preoperative
iPTH [18]. Decreased PTH concentrations lead to decreased
activation of new bone remodeling such as bone turnover and
remodeling space [15,18]. Chronically high PTH enhances
osteoclastic bone resorption and bone turnover. PTH plays a
critical role in PTH receptors on osteoblasts, which stimulate
the osteoclastic differentiation of osteoblasts and lead to
cortical bone resorption [33]. Postoperative BMD gain could
be explained by decreasing serum iPTH concentration.
The present study has a small sample size and short
prospective follow-up, a control group was not used for
comparison, and BMD in the forearm was not examined.
These are the limitations of this study.
In conclusion, parathyroidectomy provided more BMD
gain in the lumbar spine and femoral neck in symptomatic
PHPT compared to patients with asymptomatic PHPT 1 year
after parathyroidectomy. Preparathyroidectomy iPTH was an
independent predictor of BMD gain. Parathyroidectomy has
a more favorable effect on bone in patients with symptomatic
PHPT compared to patients with asymptomatic PHPT. Longterm prospective studies are required to investigate the effect
of parathyroidectomy on bone in patients with PHPT.
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